Guido Alberto Massimo Tiberio
Overview
Explore the profile of Guido Alberto Massimo Tiberio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morandi R, Guarneri C, Nardin M, Mitola S, Vettoretto N, Zanni G, et al.
Langenbecks Arch Surg
. 2024 Nov;
409(1):350.
PMID: 39551899
Purposes: Evaluate the changes in quality of life (QoL) in patients affected by tertiary hyperparathyroidism (THPT) after surgical treatment using the Parathyroidectomy Assessment of Symptoms (PAS) and Short Form-36 (SF-36)...
2.
Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al.
Gastric Cancer
. 2024 Jun;
27(4):672-674.
PMID: 38884884
No abstract available.
3.
Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al.
Gastric Cancer
. 2024 Apr;
27(4):649-671.
PMID: 38634954
Background: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy...
4.
Lagana M, Cosentini D, Tiberio G, Sigala S, Berruti A
Eur J Cancer
. 2024 Feb;
201:113602.
PMID: 38364625
No abstract available.
5.
Bencivenga M, Ministrini S, Morgagni P, Mura G, Marrelli D, Milandri C, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201597
Background: Interest in the field of metastatic gastric cancer has grown in recent years, and the identification of oligometastatic patients plays a critical role as it consents to their inclusion...
6.
Turla A, Lagana M, Abate A, Cremaschi V, Zamparini M, Chitto M, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760461
(1) Background: The standard first-line therapy for advanced adrenocortical carcinoma (ACC) is represented by EDP-M (etoposide, doxorubicin, cisplatin + mitotane). Progestins have shown cytotoxic activity both in vitro and in...
7.
Tamburello M, Abate A, Rossini E, Basnet R, Zizioli D, Cosentini D, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047801
Background: Adrenocortical cancer (ACC) is a rare malignancy with a dismal prognosis. The treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, and cisplatin). However, new therapeutic approaches for advanced ACC...
8.
Abate A, Tamburello M, Rossini E, Basnet R, Ribaudo G, Gianoncelli A, et al.
Endocr Relat Cancer
. 2022 Nov;
30(2).
PMID: 36449565
The pharmacological approach to adrenocortical carcinoma (ACC) is based on mitotane with/without etoposide, doxorubicin, and cisplatin, according to the disease stage. Considering the limited efficacy and toxicity of this treatment,...
9.
Cosentini D, Lagana M, Turla A, Tiberio G, Grisanti S, Berruti A
J Clin Endocrinol Metab
. 2022 Mar;
107(7):e3092-e3093.
PMID: 35302612
No abstract available.
10.
Solaini L, Bencivenga M, Rosa F, DIgnazio A, Marino E, Ministrini S, et al.
Tumori
. 2022 Feb;
109(1):121-128.
PMID: 35152794
Background: The coronavirus pandemic had a major impact in Italy. The Italian health system's re-organization to face the emergency may have led to significant consequences especially in the diagnosis and...